
Quarterly report 2025-Q3
added 11-10-2025
Myomo Revenue 2011-2026 | MYO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Myomo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 B | 13.9 M | 7.58 M | 3.84 M | 2.44 M | 1.56 M | 1.1 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1 B | 1.1 M | 147 M |
Quarterly Revenue Myomo
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.1 M | 9.65 M | 9.83 M | - | 9.21 M | 7.52 M | 3.75 M | - | 5.08 M | 5.96 M | 3.45 M | - | 3.97 M | 3.68 M | 3.87 M | - | 4.38 M | 3.1 M | 2.34 M | - | 1.93 M | 859 K | 1.01 M | - | 607 K | 880 K | 830 K | - | 609 K | 632 K | 313 K | - | 489 K | 307 K | 216 K | - | 184 K | 254 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.1 M | 184 K | 3.28 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Viemed Healthcare
VMD
|
270 M | $ 9.06 | 1.23 % | $ 347 M | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 38.78 | -1.25 % | $ 5.78 K | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 8.15 | 4.22 % | $ 585 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 9.69 | 3.09 % | $ 1.31 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 4.15 | 4.01 % | $ 155 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 43.13 | -0.43 % | $ 1.34 B | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
AxoGen
AXGN
|
225 M | $ 29.17 | -2.21 % | $ 1.34 B | ||
|
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.31 | 4.42 % | $ 115 M | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
64 M | $ 24.26 | 1.17 % | $ 205 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Accuray Incorporated
ARAY
|
459 M | $ 0.53 | 0.68 % | $ 54.5 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.51 | 0.05 % | $ 121 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.79 | -1.24 % | $ 43 M | ||
|
Align Technology
ALGN
|
4 B | $ 183.14 | 0.27 % | $ 13.7 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 3.99 | 7.7 % | $ 845 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
44.3 B | $ 113.59 | 0.01 % | $ 198 B | ||
|
InMode Ltd.
INMD
|
358 M | $ 13.58 | -0.18 % | $ 878 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 72.75 | -1.49 % | $ 108 B | ||
|
IRadimed Corporation
IRMD
|
73.2 M | $ 105.22 | 0.89 % | $ 1.33 B | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.42 | -0.7 % | $ 22.9 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.31 | 16.67 % | $ 1.4 M | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 13.05 | 0.23 % | $ 1.96 B | ||
|
Pulmonx Corporation
LUNG
|
83.8 M | $ 1.46 | -4.58 % | $ 57.1 M | ||
|
Medigus Ltd.
MDGS
|
29.9 M | - | 10.28 % | $ 55.5 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 95.96 | -0.8 % | $ 123 B | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 85.73 | 0.55 % | $ 50.1 B |